Sandoz Group AG SDZNY
100.43 USD +0.03 (+0.03%)
Nov 4, 2026, 11:30 AM EST
100.43 Day range 101.38
65.31 52-week range 103.22
- YTD
- +37.99%
- 1 year
- +48.54%
News
seekingalpha.com Sandoz Group AG (SDZNY) Q3 2026 Sales/Trading Call Transcript Sandoz Group AG (SDZNY) Q3 2026 Sales/Trading Call Transcript
wsj.com Sandoz Shares Fall After Company Turns Cautious on Sales Guidance Shares dropped after the company issued a more cautious outlook on top-line growth for 2026, citing challenging conditions in Germany and supply constraints for biosimilar drugs.
reuters.com Generic drugmaker Sandoz lowers sales outlook, lifts profit forecast Swiss generic drugmaker Sandoz on Wednesday lowered its full-year sales growth guidance and lifted its core earnings margin forecasts after short-term biosimilar-supply constraints weighed on
zacks.com NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now? Investors interested in stocks from the Medical - Drugs sector have probably already heard of Neurocrine Biosciences (NBIX) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two companies…
zacks.com GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now? Investors with an interest in Medical - Drugs stocks have likely encountered both Grifols (GRFS) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two stocks presents investors with the…
prnewswire.com mAbxience and Sandoz Sign a Collaboration Agreement to Advance Biosimilar Access Worldwide mAbxience and Sandoz have entered into a collaboration agreement combining mAbxience's development and manufacturing expertise with Sandoz's global commercial capabilities for a proposed emicizumab…
wsj.com Sandoz Gets Canada Approval for Generic Version of Ozempic The approval for its generic version of diabetes drug Ozempic advances its efforts to build a portfolio of GLP-1 medicines.
seekingalpha.com Sandoz Group AG (SDZNY) Analyst/Investor Day Transcript Sandoz Group AG (SDZNY) Analyst/Investor Day Transcript
zacks.com GRFS or SDZNY: Which Is the Better Value Stock Right Now? Investors interested in Medical - Drugs stocks are likely familiar with Grifols (GRFS) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two companies is the best option for those looking…
reuters.com Switzerland's Sandoz pivots to biosimilars, expects rapid mid-term growth Sandoz aims to more than double net sales from 2025 to 2035, the Swiss drug maker said on Tuesday at its capital markets day, where it outlined its new Bio100 biosimilars strategy, pivoting its…
zacks.com 3 Generic Drug Stocks to Watch Amid Improving Industry Trends The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.
prnewswire.com Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages Based on the…
reuters.com Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech Swiss generic drugmaker Sandoz will pay up to $77 million upfront to Shanghai Henlius Biotech for rights to three biosimilar drugs to treat cholesterol, lupus and colorectal cancer, the Chinese…
seekingalpha.com Sandoz Group AG (SDZNY) Q2 2026 Earnings Call Transcript Sandoz Group AG (SDZNY) Q2 2026 Earnings Call Transcript
wsj.com Sandoz Shares Climb After Biosimilar Sales Drive Growth Sandoz Group reported higher sales for the second quarter, driven by a strong performance in its biosimilar segment and a return to growth in generics.
reuters.com Sandoz results narrowly beat sales expectations Swiss generic maker Sandoz reported a 9% jump in second quarter net sales on Wednesday, slightly above analyst expectations, as it reaped the benefits of patent expirations in its…
zacks.com UTHR or SDZNY: Which Is the Better Value Stock Right Now? Investors interested in Medical - Drugs stocks are likely familiar with United Therapeutics (UTHR) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two companies is the best option for…
wsj.com Sandoz to Pay Around $480 Million to Settle U.S. Antitrust Pricing Litigations The agreements mean the remaining claims against the Swiss maker of generic drugs in the U.S. generic antitrust litigation are those from individual plaintiffs.
reuters.com Sandoz agrees $450 mln settlement with 43 US states over antitrust claims Swiss generic drugmaker Sandoz said on Monday that it has entered into a $450 million settlement agreement with 43 U.S. states and territories to resolve litigations concerning alleged…
reuters.com Generic drug sector seeks policy fixes after Trump tariff threat The generic drug market still faces structural and purchasing hurdles despite strong U.S. growth, an industry group noted on Wednesday, after President Donald Trump said imported generic medicines…
benzinga.com Evotec Closed Its Previously Reported Sale Of The Just-evotec Biologics Toulouse Site Plus An Indefinite Technology License To Its Continuous Manufacturing Platform Technology To Sandoz, Potential Payments Of Over $650M Plus Royalties Of Up To 10 Biosimilar Molecules All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing of contract in NovemberAgreement includes approximately US$ 350 m in cash for Just…
benzinga.com Evotec To Sell Evotec Biologics Toulouse Facility To Sandoz AG For ~$350M In Cash Evotec SE (Frankfurt Stock Exchange:EVT, SDAX/TecDAX, Prime Standard, TRQX:EVTd(TRQX:EVTdFTRQX:EVTdrTRQX:EVTdaTRQX:EVTdnTRQX:EVTdkTRQX:EVTdfTRQX:EVTduTRQX:EVTdrTRQX:EVTdtTRQX:EVTd
benzinga.com Evotec To Sell Just-Evotec Biologics Toulouse Site To Sandoz For $300M Cash Plus Royalties, Marking Shift To Asset-Lighter Model Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just - Evotec Biologics EU in Toulouse to SandozUnder the proposed deal Evotec would transfer biosimilar manufacturing…